Q2 2026 revenue grew 20% year-over-year to $103.5 million, with strong volume growth in TissueCypher and DecisionDx-Melanoma. 2026 revenue guidance was raised to $365–$375 million, and positive adjusted EBITDA is expected for the remainder of 2026.Based on Castle Biosciences, Inc. [CSTL] Q2 2026 Au…
Q2 2026 revenue grew 20% year-over-year to $103.5 million, with strong volume growth in TissueCypher and DecisionDx-Melanoma. 2026 revenue guidance was raised to $365–$375 million, and positive adjusted EBITDA is expected for the remainder of 2026.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
